Dehydroepiandrosterone (DHEA) and systemic lupus erythematosus

Semin Arthritis Rheum. 1998 Jun;27(6):335-47. doi: 10.1016/s0049-0172(98)80013-9.

Abstract

Objective: This study was performed to evaluate in vivo and in vitro data on the effects of the adrenal steroid dehydroepiandrosterone (DHEA) with emphasis on its potential use in the treatment of systemic lupus erythematosus (SLE).

Methods: The literature dealing with DHEA was reviewed.

Results: Initially, research on DHEA focused on effects of DHEA in relation to obesity. Over the past decade, research stimulated by associations between the physiological decline in DHEA and aging, cardiovascular disease, changes in metabolism, brain function, and immune senescence have generated insight into the many effects that DHEA or its metabolites may have. In SLE a role for sex hormones in both the etiopathogenesis and disease activity is recognized. In SLE, as in aging, low DHEA levels are frequently found, especially with corticosteroid treatment.

Conclusions: Research data in the elderly, on both hormonal and immunologic effects, suggest that DHEA may become an adjunctive treatment for SLE patients.

Publication types

  • Review

MeSH terms

  • Aged
  • Aged, 80 and over
  • Animals
  • Clinical Trials as Topic
  • Dehydroepiandrosterone / physiology
  • Dehydroepiandrosterone / therapeutic use*
  • Drug Administration Routes
  • Gonadal Steroid Hormones / blood
  • Humans
  • In Vitro Techniques
  • Lupus Erythematosus, Systemic / drug therapy*
  • Lupus Erythematosus, Systemic / physiopathology
  • Sex Hormone-Binding Globulin / drug effects

Substances

  • Gonadal Steroid Hormones
  • Sex Hormone-Binding Globulin
  • Dehydroepiandrosterone